Gut Microbiota-Derived Imidazole Propionate as a Predictor of Cardiometabolic Risk in Coronary Artery Disease: Evidence and Clinical Implications
Posted inCardiology Clinical Updates Gastroenterology news

Gut Microbiota-Derived Imidazole Propionate as a Predictor of Cardiometabolic Risk in Coronary Artery Disease: Evidence and Clinical Implications

Emerging evidence identifies circulating imidazole propionate, a gut microbiota-derived metabolite, as an independent predictor of major adverse cardiovascular events in patients with coronary artery disease, offering novel insights into personalized risk stratification and therapeutic targets.
Validating Liver Stiffness Measurement as a Prognostic Tool in Primary Sclerosing Cholangitis: Insights from the Prospective FICUS Cohort
Posted inGastroenterology news

Validating Liver Stiffness Measurement as a Prognostic Tool in Primary Sclerosing Cholangitis: Insights from the Prospective FICUS Cohort

This prospective study confirms that liver stiffness measurement (LSM) by Fibroscan® effectively predicts transplant-free survival in primary sclerosing cholangitis (PSC), highlighting both static and dynamic assessments as powerful risk stratification and potential clinical trial endpoints.
Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4
Posted inClinical Updates Diabetes & Endocrinology Gastroenterology news

Liver, Portal, and Systemic Thyroid Hormone Alterations in End-Stage MASH: Distinct Diagnostic and Prognostic Roles for T3/rT3 Ratio and T4

End-stage metabolic dysfunction-associated steatohepatitis (MASH) features profound disruptions in thyroid hormone metabolism across liver, portal, and systemic compartments, with the hepatic T3 level and systemic T3/rT3 ratio serving as sensitive diagnostic biomarkers and systemic T4 correlating with disease severity.